

Learner Notification

MED Learning Group

Challenging Clinical Decisions in Cancer Immunotherapy: First-Line Treatment of Advanced Non-small Cell Lung Cancer

August 4, 2023 – August 4, 2024

Online

Acknowledgement of Financial Commercial Support

Regeneron Pharmaceuticals, Inc.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 0.25 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Evaluate recent first-line, mono-immunotherapy clinical trials data in the treatment of patients with advanced NSCLC without targetable mutations.
2. Discuss the first-line, immunotherapy combination regimen clinical data in the management of patients with advanced NSCLC.
3. Review the use of clinical practice guidelines in the management of patients with advanced NSCLC and no targetable mutations.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1--6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interst: Relationship
Russie	Allen	NA
Debora S.	Bruno	Amgen, Bristol Meyers Squibb, Novartis, Eli Lilly, Daiichi-Sankyo, AstraZeneca, Mirati Therapeutics: Consultant, Bristol Meyers Squibb, Dragonfly Therapeutics, Mirati Therapeutics, Daiichi-Sankyo, AstraZeneca, Genentech, Seagen: Contracted Rsearch
Millena	De Brito	NA
Matthew	Frese	NA
Christina	Gallo	NA
Amanda	Jenkins	NA
Melissa A.	Johnson	NA
Michael	Page	NA
Jo	Shultz	NA

Lauren	Welch	NA
--------	-------	----

Questions? Email Certificate@AmedcoEmail.com